Edition:
United Kingdom

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.65USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
146,378
52-wk High
$5.50
52-wk Low
$1.08

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $55.98
Shares Outstanding(Mil.): 22.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

09 Nov 2017

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

04 Oct 2017

BRIEF-Catabasis Pharmaceuticals Q2 loss per share $0.32

* Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress

10 Aug 2017

Earnings vs. Estimates